Seeking Alpha
 

St. Jude Medical, Inc. (STJ)

- NYSE
  • Apr. 18, 2012, 7:44 AM
    St. Jude Medical (STJ): Q1 EPS of $0.86 beats by $0.03. Revenue of $1.4B (+1.4% Y/Y) in-line. (PR)
    | Comment!
  • Apr. 18, 2012, 12:05 AM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 5:30 PM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 1:21 PM
    Canaccord is recommending buying St. Jude Medical (STJ +2%) ahead of its upcoming Q1 report. The firm sees an in-line quarter but feels 2012 guidance is too conservative, saying that with signs of CRM stabilization and new product pipelines, the stocks recent weakness presents a decent buying opportunity for longer-term investors.
    | Comment!
  • Apr. 9, 2012, 2:33 PM
    St. Jude Medical (STJ -4.8%) shares sink after calling attention to a medical journal article that shows Medtronic's (MDT -0.9%) heart device leads resulted in fewer deaths than its recalled Riata and Riata ST products. STJ says the article "substantially undercounted" deaths associated with MDT's Quattro Secure device and wants it retracted.
    | Comment!
  • Apr. 4, 2012, 10:24 AM
    St. Jude Medical (STJ -5.3%) will stop selling its QuickSite and QuickFlex left-ventricular leads, wires that help pace the heart in patients with heart failure, after 39 reports of the wires protruding from their insulation. STJ has been dealing with the same problem in its recalled Riata wires that connect life-saving defibrillators to the heart.
    | Comment!
  • Apr. 2, 2012, 12:21 PM
    Lazard Capital downgrades a number of names in the in the Medical Technology space today due to valuation. Intuitive Surgical (ISRG +0.2%), Endologix (ELGX -5.4%), Allergan (AGN -0.4%), St. Jude Medical (STJ -0.7%) and ZOLL Medical (ZOLL +0.1%) are all cut to Neutral.
    | 1 Comment
  • Mar. 27, 2012, 10:21 AM
    Researchers say St. Jude Medical's (STJ +2.1%) recalled Riata wires, used to connect life-saving defibrillators to the heart, can short circuit, a defect that may have led to 22 deaths. Riata and Riata ST wires “are prone to high-voltage failures that have resulted in death,” according to a study to be published.
    | Comment!
  • Mar. 19, 2012, 2:13 PM
    Kensey Nash (KNSY +24%) jumps after saying it's reached a settlement with St. Jude Medical (STJ -0.6%), resolving its dispute regarding vascular closure device licenses and related claims. Under the deal, St. Jude will pay Kensey $39 million over several quarters.
    | Comment!
  • Mar. 6, 2012, 12:51 PM
    St. Jude Medical (STJ -3.2%) reports a $56M charge for losses in Greece when it failed to receive payments from a distributor. While STJ says revenue from Greece does not impact its 2012 guidance, Citigroup's Matthew Dodds says the "exceedingly large" size of the write-off "makes it pretty clear this was their primary channel" in the country. (also)
    | Comment!
  • Feb. 17, 2012, 10:26 AM
    Edwards Lifesciences (EW) is taking unusual caution in introducing its Sapien heart valve to help ensure good results, a departure from the typical industry strategy of flooding the market to take advantage of a head start. But the strategy is risky, as rivals nip at its heels; a MDT device is available in Europe, and BSX and STJ could have products ready soon.
    | Comment!
  • Feb. 6, 2012, 2:20 PM
    St. Jude Medical (STJ +1%) outperforms after UBS reiterates a Buy following the company's Feb. 3 investor meeting. The firm touts the strength of St. Jude's product pipeline, and expects recent weakness in ICD product sales to be offset by strength in other areas. It also doesn't see "any evidence of a problematic defect" in St. Jude's Durata defilibration lead, in spite of concerns to the contrary.
    | Comment!
  • Feb. 3, 2012, 7:51 AM
    A new government report shines a bright spotlight on the pricing of high-priced medical devices with cost variance ranging as much as 50% across different hospitals for the purchases of the same products. The GAO report raises "serious concerns" over the prices hospitals and Medicare pay for medical devices, as well as stoking up Congressional backlash on the issue. Companies that could be impacted by pricing reform include MDT, BAX, COV, SYK, TMO, ISRG, BDX, STJ, EW, BSX, BCR, VAR.
    | 1 Comment
  • Jan. 26, 2012, 9:37 AM
    Canaccord Genuity upgrades shares of St. Jude Medical (STJ -0.5%) to a Buy rating from Hold with an improved price target of $50. Analysts call the firm's 2012 guidance "light," as they see modestly accelerated growth rates in 2013 and a promising pipeline.
    | Comment!
  • Jan. 25, 2012, 1:22 PM
    St. Jude Medical (STJ +3.2%) trades up after its Q4 beat expectations across the board. Despite the earnings beat and today's price action, profit dipped 21% Y/Y as cardiac rhythm management sales declined due to concerns of overuse and a DOJ investigation. Like most of the industry, STJ continues to be challenged by pricing pressures from hospitals and more potential cuts in government health-care spending.
    | 1 Comment
  • Jan. 25, 2012, 7:39 AM
    St. Jude Medical (STJ): Q4 EPS of $0.86 beats by $0.02. Revenue of $1.41B (+4.2% Y/Y) beats by $10M. (PR)
    | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.